Press Release Source: Calypte Biomedical Corporation
Calypte Biomedical Receives Letter of Intent For $4 Million Purchase Order From World Vision Africa
Tuesday September 16, 11:09 am ET
ALAMEDA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT - News), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test announced today that it has received a letter from World Vision Africa, one of the largest NGOs (non-government organization) in Africa, outlining an intent to purchase $4 million of Calypte's urine based HIV/AIDS tests.
In a letter dated September 16, 2003, Mr. Dida Guyo, Procurement Officer for World Vision's Africa Regional Office in Nairobi, Kenya, stated that World Vision Africa spends over $1 million quarterly on HIV tests and that World Vision Africa commits to change this quarterly purchase of HIV tests from the standard blood tests to Calypte Biomedical's urine based HIV/AIDS test.
The purchase is contingent upon the imminent approval of Calypte's urine based tests by the Kenyan National Laboratory. Mr. Guyo stated that since the urine tests have been approved by the FDA, WHO and in neighboring Uganda, then he sees the Kenyan approval process a formality. Mr. Guyo also stated that there is strong support in Africa for non-invasive HIV/AIDS tests.
Jay Oyakawa, President of Calypte stated, "We are aggressively coordinating our efforts to receive final approval from the Republic of Kenya and believe that approval is imminent."
About World Vision:
World Vision is an international Christian relief and development organization working to promote the well being of all people -- especially children. In 2002, World Vision offered material, emotional, social and spiritual support to 85 million people in 96 countries.
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com .
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
Investor Relations Contact:
Tim Clemensen
212-843-9337
e-mail: tclemensen@rubensteinir.com
--------------------------------------------------
Source: Calypte Biomedical Corporation |
Thread abonnieren
